Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ViroPharma: SGP 'nose' best

Even before FDA declined to approve an oral formulation of pleconaril in 2002 for the treatment of viral respiratory infections, there were some who wondered whether a product to treat the common cold would be used and reimbursed in today's healthcare environment. Schering-Plough Corp. is betting that the answer is yes.

Last week, SGP paid $10 million to ViroPharma Inc. for

Read the full 611 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers